Halaven (Page 7 of 7)

PRINCIPAL DISPLAY PANEL

NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)For Intravenous Use

PRINCIPAL DISPLAY PANEL
NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)
For Intravenous Use
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)For Intravenous Use

PRINCIPAL DISPLAY PANEL
NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)
For Intravenous Use
(click image for full-size original)

HALAVEN eribulin mesylate injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:62856-389
Route of Administration INTRAVENOUS DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ERIBULIN MESYLATE (ERIBULIN) ERIBULIN MESYLATE 0.5 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
ALCOHOL
WATER
SODIUM HYDROXIDE
HYDROCHLORIC ACID
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:62856-389-01 1 VIAL, SINGLE-DOSE in 1 CARTON contains a VIAL, SINGLE-DOSE
1 2 mL in 1 VIAL, SINGLE-DOSE This package is contained within the CARTON (62856-389-01)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA201532 11/15/2010
Labeler — Eisai Inc. (189246791)

Revised: 12/2021 Eisai Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.